CELEBRATING
th
ANNIVERSARY
Dr Habil Khorakiwala appointed Chancellor of Jamia Hamdard University Dr Habil Khorakiwala has accepted to be the Chancellor of our University. With his established leadership and interest in science and technology, the University would benefit from his direction and guidance.” Dr Habil Khorakiwala is a recipient of the prestigious Shiromani Vikas Award for his ‘Outstanding and Inspiring Contribution towards National Development.’ He received it at the hands of Mother Teresa (1992). He has also served as the President of Federation of Indian Chambers of Commerce & Industry (FICCI) and Indian Pharmaceutical Alliance (IPA), and has sat on the board of several prestigious advisory boards for the Government of India. Dr Khorakiwala has also served as the Honorary Consul General of Sweden in Mumbai.
The Founder Chairman of Wockhardt Group will occupy the new position for five years JAMIA HAMDARD University has appointed Dr Habil Khorakiwala as its new Chancellor. Dr Khorakiwala will occupy the position for five years beginning December 2014. Dr Habil Khorakiwala is the Chairman of Wockhardt Group, a leading healthcare provider. Talking on the appointment, Dr Habil Khorakiwala, said, “I intend to create a vision for the Jamia Hamdard University - to be at the forefront of imparting right education and knowledge in the 21st century.” Over the last ten years, Jamia Hamdard has emerged as a leading institution of higher learning with distinct and focused academic programmes.
Besides having a medical college and healthcare facility, it also has graduate programmes in information technology (IT) and computer applications. It also has post-graduate programmes in IT, computer applications, business management, physiotherapy and occupational therapy have been started. Undergraduate programmes in physiotherapy and occupational Therapy are being introduced from this year. Jamia Hamdard offers post-graduate and doctoral programmes in several disciplines for which advanced facilities are available. Dr GN Qazi, Vice Chancellor, Jamia Hamdard University, said, “We are indeed happy that
Venkatadri Bobba joins Cancer Genetics India’s Board of Directors Bobba has over 36 years of corporate leadership experience in the pharma and life sciences industries CANCER GENETICS, provider of DNA-based cancer diagnostics, has announced the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors. “Bobba has a tremendous track record of leadership in the life sciences. His experiences and insights will bring significant value to CG India’s board of directors,” said Panna Sharma, CEO and President of Cancer Genetics. Bobba has over 36 years of
corporate leadership experience in the pharma and life sciences industries, informs a company release. Bobba, who is currently a General Partner with Ventureast, has held executive leadership positions at a number of life sciences companies in the US, EU, and Asia. Prior to joining Ventureast, Bobba served as Senior VP of Operations at Aradigm Corporation and from 2001-2003 was Executive Vice President at Diosynth, a division of Akzo Nobel. From
1995 to 2000, Bobba served as President and CEO at Molecular Biosystems. Previous to that, Bobba was Executive Vice President of Centocor Inc (now Jansen Biotech, a division of Johnson & Johnson) and held several executive positions, including President, at WarnerLambert, Indonesia. He also previously served as VP of Manufacturing at Parke-Davis, USA (now part of Pfizer). “It is an exciting time to be part of such a high-growth market like India. I look forward to the growth and much needed innovation that CG India will bring to Indian cancer patients and hospitals at an affordable price,” said Bobba. “CG India has established itself as a leader in
the oncology diagnostics market with a firm commitment to innovation. I look forward to helping the company offer novel cancer diagnostic tests to all patients who needs them to improve
their clinical outcomes.” Bobba is an active board member of three US-based companies, including Diabetomics, Melior Pharma, and Sparsha. Bobba also sits on the board of several Indian-based companies, including Portea, Richcore, and Sparsha Pharma, an Indian subsidiary of Napo Pharmaceuticals. Additionally, he serves on the advisory board for the SOHO Group, the largest pharma company in Indonesia, and for Cumberland Pharmaceuticals, US. A pharmacist by training, Bobba graduated with gold medal honors from Andhra University and holds an MBA from Farleigh Dickinson University, New Jersey.
EXPRESS HEALTHCARE
61
January 2015